Opthea (ASX:OPT), an Australian clinical-stage biopharmaceutical company developing novel biologic therapies to treat eye diseases, has reported positive results from its Phase 2b trial of OPT-302 for wet age-related macular degeneration (AMD). …
Latest Video
New Stories
-
The 'Week in Review' Podcast - 21 February
February 21, 2025 - - Podcast -
PSA members endorse acquisition of the Australasian College of Pharmacy
February 21, 2025 - - Latest News -
Significant gift new Academy for Health Leadership at University of Melbourne
February 21, 2025 - - Latest News -
First and only treatment for chronic hypoparathyroidism approved in Australia
February 21, 2025 - - Latest News -
AstraZeneca maintains its lead as other teams start to build
February 21, 2025 - - Latest News -
A good idea that will need to overcome an institutional mindset
February 19, 2025 - - Latest News -
Pharmaceuticals the latest Trump target for tariffs
February 19, 2025 - - Latest News